Tracey-Lea Laba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4876876/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abortion Safety and Use with Normally Prescribed Mifepristone in Canada. New England Journal of Medicine, 2022, 386, 57-67.	13.9	34
2	Pharmacist's time spent: Space for Pharmacy-based Interventions and Consultation TimE (SPICE)—an observational time and motion study. BMJ Open, 2022, 12, e055597.	0.8	7
3	Australian hospital outpatient pharmacies: service adaptations during the 2020 national coronavirus disease 2019 lockdown. Journal of Pharmacy Practice and Research, 2022, 52, 326-328.	0.5	3
4	Outâ€ofâ€pocket spending among a cohort of Australians living with gout. International Journal of Rheumatic Diseases, 2021, 24, 327-334.	0.9	7
5	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	0.7	48
6	An electronic decision supportâ€based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). Medical Journal of Australia, 2021, 214, 420-427.	0.8	7
7	Assessing the impact of a combined nutrition counselling and cash transfer intervention on women's empowerment in rural Bangladesh: a randomised control trial protocol. BMJ Open, 2021, 11, e044263.	0.8	1
8	Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future. International Journal of Environmental Research and Public Health, 2021, 18, 13345.	1.2	11
9	Cost-related nonadherence to medicines in people with multiple chronic conditions. Research in Social and Administrative Pharmacy, 2020, 16, 415-421.	1.5	8
10	Shonjibon cash and counselling: a community-based cluster randomised controlled trial to measure the effectiveness of unconditional cash transfers and mobile behaviour change communications to reduce child undernutrition in rural Bangladesh. BMC Public Health, 2020, 20, 1776.	1.2	4
11	Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience. International Journal of Technology Assessment in Health Care, 2020, 36, 434-439.	0.2	6
12	Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics, 2020, 38, 1165-1185.	1.7	25
13	Community pharmacist workflow: Space for Pharmacy-based Interventions and Consultation TimE study protocol. International Journal of Pharmacy Practice, 2020, 28, 441-448.	0.3	2
14	Who benefits most from extending financial protection for cataract surgery in Vietnam? An extended cost-effectiveness analysis of small incision surgery. Health Policy and Planning, 2020, 35, 399-407.	1.0	2
15	Formulating an Ethics of Pharmaceutical Disinvestment. Journal of Bioethical Inquiry, 2020, 17, 75-86.	0.9	4
16	QUality improvement in primary care to prevent hospitalisations and improve Effectiveness and efficiency of care for people Living with coronary heart disease (QUEL): protocol for a 24-month cluster randomised controlled trial in primary care. BMC Family Practice, 2020, 21, 36.	2.9	9
17	Optimising TRIUMPH with 6·25 mg chlorthalidone – Authors' reply. The Lancet Global Health, 2020, 8, e176.	2.9	0
18	What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan. Health Policy, 2020, 124, 977-983.	1.4	6

TRACEY-LEA LABA

#	Article	IF	CITATIONS
19	General practitioners' views on the influence of cost on the prescribing of asthma preventer medicines: a qualitative study. Australian Health Review, 2019, 43, 246.	0.5	5
20	Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart, 2019, 105, 42-48.	1.2	45
21	Cost-Related Underuse of Medicines for Asthma—Opportunities for Improving Adherence. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2298-2306.e12.	2.0	36
22	Impact of a household-level deductible on prescription drug use among lower-income adults: a quasi-experimental study. CMAJ Open, 2019, 7, E167-E173.	1.1	7
23	Mâ€SAKHI—Mobile health solutions to help community providers promote maternal and infant nutrition and health using a communityâ€based cluster randomized controlled trial in rural India: A study protocol. Maternal and Child Nutrition, 2019, 15, e12850.	1.4	15
24	Process evaluations of primary care interventions addressing chronic disease: a systematic review. BMJ Open, 2019, 9, e025127.	0.8	23
25	Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis. Pharmacoeconomics, 2019, 37, 227-238.	1.7	4
26	Patient Perceptions of Treatment Delivery Platforms for Cognitive Behavioral Therapy for Insomnia. Behavioral Sleep Medicine, 2019, 17, 81-97.	1.1	12
27	Patient Preferences for Managing Insomnia: A Discrete Choice Experiment. Patient, 2018, 11, 503-514.	1.1	11
28	Action to address the household economic burden of non-communicable diseases. Lancet, The, 2018, 391, 2047-2058.	6.3	170
29	Investigation of attributes which guide choice in cataract surgery services in urban Sydney, Australia. Australasian journal of optometry, The, 2018, 101, 363-371.	0.6	10
30	Considering pharmacy workflow in the context of Australian community pharmacy: A pilot time and motion study. Research in Social and Administrative Pharmacy, 2018, 14, 1157-1162.	1.5	13
31	Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. International Journal of Cardiology, 2018, 262, 71-78.	0.8	18
32	To Drug or Not to Drug: A Qualitative Study of Patients' Decision-Making Processes for Managing Insomnia. Behavioral Sleep Medicine, 2018, 16, 1-26.	1.1	39
33	Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants. PLoS ONE, 2018, 13, e0208824.	1.1	29
34	Process evaluation of a randomised controlled trial of a pharmacological strategy to improve hypertension control: protocol for a qualitative study. BMJ Open, 2018, 8, e022317.	0.8	1
35	Medication non-adherence in a cohort of chronically ill Australians: A case of missed opportunities. Australian Journal of General Practice, 2018, 47, 556-562.	0.3	3
36	Making guidelines for economic evaluations relevant to public health in Australia. Australian and New Zealand Journal of Public Health, 2017, 41, 115-117.	0.8	7

TRACEY-LEA LABA

#	Article	IF	CITATIONS
37	A priority-setting framework is needed to understand the value of investing in a universal drug plan. Cmaj, 2017, 189, E704-E704.	0.9	0
38	Using administrative data to look at changes in the level and distribution of out-of-pocket medical expenditure: An example using Medicare data from Australia. Health Policy, 2017, 121, 426-433.	1.4	16
39	Mapping the illness trajectories of insomnia: a biographical disruption?. Sociology of Health and Illness, 2017, 39, 659-679.	1.1	4
40	Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. International Journal for Equity in Health, 2017, 16, 108.	1.5	7
41	Creating a new investment pool for innovative health systems research. Australian Health Review, 2017, 41, 173.	0.5	0
42	Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. BMJ Open, 2017, 7, e017281.	0.8	9
43	Drivers of choice of resuscitation fluid in the intensive care unit: a discrete choice experiment. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2017, 19, 134-141.	0.0	1
44	Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. European Journal of Preventive Cardiology, 2016, 23, 1065-1076.	0.8	43
45	Examining the use of process evaluations of randomised controlled trials of complex interventions addressing chronic disease in primary health care—a systematic review protocol. Systematic Reviews, 2016, 5, 138.	2.5	15
46	Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease. JAMA Internal Medicine, 2016, 176, 340.	2.6	580
47	Co-payments for health care: what is their real cost?. Australian Health Review, 2015, 39, 33.	0.5	23
48	An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. Implementation Science, 2015, 11, 129.	2.5	7
49	Implementing Kanyini CAP, a pragmatic randomised controlled trial in Australia: findings from a qualitative study. Trials, 2015, 16, 425.	0.7	7
50	Financing options to sustain Medicare: are we committed to universalism?. Medical Journal of Australia, 2015, 203, 244-245.	0.8	4
51	Facilitators and barriers to implementation of a pragmatic clinical trial in Aboriginal health services. Medical Journal of Australia, 2015, 203, 24-27.	0.8	13
52	Patient Preferences for a Polypill for the Prevention of Cardiovascular Diseases. Annals of Pharmacotherapy, 2015, 49, 528-539.	0.9	22
53	The effectiveness of interventions to reduce the household economic burden of illness and injury: a systematic review. Bulletin of the World Health Organization, 2015, 93, 102-112B.	1.5	16
54	Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China. American Heart Journal, 2015, 169, 349-355.	1.2	24

TRACEY-LEA LABA

#	Article	IF	CITATIONS
55	Understanding Patient Preferences in Medication Nonadherence: A Review of Stated Preference Data. Patient, 2015, 8, 385-395.	1.1	18
56	Patients' and Providers' Perspectives of a Polypill Strategy to Improve Cardiovascular Prevention in Australian Primary Health Care. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 301-308.	0.9	29
57	Understanding if, how and why non-adherent decisions are made in an Australian community sample: A key to sustaining medication adherence in chronic disease?. Research in Social and Administrative Pharmacy, 2015, 11, 154-162.	1.5	27
58	Evaluating the costs and benefits of using combination therapies. Medical Journal of Australia, 2014, 201, 447-448.	0.8	1
59	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Medical Journal of Australia, 2014, 201, 671-673.	0.8	18
60	The household economic burden of eating disorders and adherence to treatment in Australia. BMC Psychiatry, 2014, 14, 338.	1.1	23
61	Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?. Arthritis Research and Therapy, 2014, 16, 106.	1.6	5
62	Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskeletal Disorders, 2013, 14, 160.	0.8	71
63	Strategies to improve adherence to medications for cardiovascular diseases in socioeconomically disadvantaged populations: A systematic review. International Journal of Cardiology, 2013, 167, 2430-2440.	0.8	36
64	INterpreting the Processes of the UMPIRE Trial (INPUT): protocol for a qualitative process evaluation study of a fixed-dose combination (FDC) strategy to improve adherence to cardiovascular medications. BMJ Open, 2013, 3, e002313.	0.8	5
65	Understanding rational non-adherence to medications. A discrete choice experiment in a community sample in Australia. BMC Family Practice, 2012, 13, 61.	2.9	21
66	What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study. BMJ Open, 2011, 1, e000372-e000372.	0.8	14